Related Experiment Video
Updated: Aug 7, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Wee1 inhibitor PD0166285 sensitized TP53 mutant lung squamous cell carcinoma to cisplatin via STAT1
Qi Li1,2, Wenjie Yang3, Qingyi Zhang4
1Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou, 310058, China.
Background:
Lung squamous cell carcinoma (LUSCs) is associated with high mortality (20-30%) and lacks of effective treatments. Almost all LUSC exhibit somatic mutations in TP53. Wee1, a tyrosine kinase, regulates the cell cycle at the G2/M checkpoint. In TP53-deficient cells, the dependence on G2/M checkpoints increases. PD0166285 is the first reported drug with inhibitory activity against both Wee1 and PKMYT1.
Methods:
Protein expression was determined by Western blot analysis. Cell proliferation was assessed using cell colony formation and CCK-8 assays. Cell cycle was performed by PI staining with flow cytometry. Apoptosis was evaluated using Annexin V-Phycoerythrin double staining and flow cytometry. DNA damage was detected through comet assay and immunofluorescence assay. In vivo, apoptosis and anti-tumor effects were assessed using the TUNEL assay, a nude mouse model, and immunohistochemistry (IHC). Co-immunoprecipitation assay was used to detect protein-protein interactions. We analyzed Wee1, PKMYT1, and Stat1 expression in pan-cancer studies using the Ualcan public database and assessed their prognostic implications with Kaplan-Meier curves.
Result:
PD0166285, a Wee1 inhibitor, effectively inhibits Wee1 activity, promoting cell entry into a mitotic crisis. Moreover, PD0166285 sensitizes cells to cisplatin, enhancing clinical outcomes. Our study demonstrated that PD016628 regulates the cell cycle through Rad51 and results in cell cycle arrest at the G2/M phase. We observed increased apoptosis in tumor cells treated with PD0166285, particularly when combined with cisplatin, indicating an enhanced apoptotic response. The upregulation of γ-H2AX serves as an indicator of mitotic catastrophe. Co-immunoprecipitation and data analysis revealed that apoptosis in LUSC is mediated through the Stat1 pathway, accompanied by decreased levels of Socs3. Furthermore, IHC staining confirmed significant differences in the expression of Phospho-CDK1 and γ-H2AX in LUSCs, suggesting involvement in DNA damage.
Conclusions:
In summary, our study suggests that PD0166285, an inhibitor of Wee1, sensitizes LUSC cells to cisplatin and modulates DNA damage and apoptosis pathways through Rad51 and Stat1, respectively. These findings highlight the combination of PD0166285 and cisplatin as a promising therapeutic approach for treating LUSC.
Insights
This study shows that PD0166285, a Wee1 inhibitor, enhances cisplatin treatment for lung squamous cell carcinoma (LUSC) by promoting DNA damage and apoptosis. This combination offers a promising new therapy for LUSC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Lung squamous cell carcinoma (LUSC) has high mortality and limited effective treatments, often linked to TP53 mutations.
- Wee1 kinase regulates the G2/M cell cycle checkpoint, which becomes critical in TP53-deficient cancers.
- PD0166285 is a novel dual inhibitor of Wee1 and PKMYT1.
Purpose of the Study:
- To investigate the efficacy of PD0166285 as a monotherapy and in combination with cisplatin for LUSC.
- To elucidate the molecular mechanisms underlying PD0166285's anti-cancer effects in LUSC.
- To evaluate the therapeutic potential of targeting Wee1 in LUSC.
Main Methods:
- Western blot, CCK-8, colony formation assays for protein expression and proliferation.
- Flow cytometry for cell cycle and apoptosis analysis.
- Comet assay, immunofluorescence, TUNEL assay, and IHC for DNA damage and apoptosis.
- Co-immunoprecipitation for protein interactions.
- Pan-cancer analysis of Wee1, PKMYT1, Stat1 expression and prognostic value using Ualcan and Kaplan-Meier curves.
Main Results:
- PD0166285 inhibits Wee1, inducing mitotic crisis and G2/M cell cycle arrest via Rad51.
- Combination therapy with PD0166285 and cisplatin significantly enhanced apoptosis and anti-tumor effects.
- Apoptosis in LUSC was mediated by the Stat1 pathway, with decreased Socs3 levels.
- Upregulation of γ-H2AX and Phospho-CDK1 indicated DNA damage and mitotic catastrophe.
Conclusions:
- PD0166285, a Wee1 inhibitor, sensitizes LUSC cells to cisplatin.
- The combination modulates DNA damage and apoptosis through Rad51 and Stat1 pathways.
- Targeting Wee1 with PD0166285 in combination with cisplatin presents a promising therapeutic strategy for LUSC.
